TO THE EDITORS
I just read the commentary by McMahon et al.1 I very much support their arguments and would like to share a 30-year-old anecdote.
In the early 1970s, as a graduate student at Carnegie-Mellon University, I was involved in a project that applied cost-effectiveness analysis to medical screening tests in use at that time, one of which was Pap smears. The faculty concluded that cervical cancer screening was not cost effective, based on a mathematical model that used the low overall incidence of cervical cancer, among many other inputs. I and another student independently re-did the analysis, separating the data by ethnicity and age. We found that screening guidelines should vary by both the woman's ethnicity and age.
Thirty years on, this concept of targeting screening or treatment to those for whom it would most benefit and not providing it to those for whom it would least benefit is still not accepted. Some may say this is rationing–if so, it is rationing based on clinical and epidemiologic information. In a society with limited resources for government programs such as Medicare and Medicaid, and with 48 million people without health insurance coverage, rationing based on clinical and epidemiologic information is preferable to rationing based on economic criteria.
W. P. Carey School of Business
Bradford Kirkman-Liff, DrPH
Telephone Follow-Up on Medicare Patient Surveys Remains Critical
January 16th 2025Including a telephone component in Medicare Consumer Assessment of Healthcare Providers and Systems survey administration continues to be valuable because telephone responses comprise a substantial portion of responses for several underserved groups.
Read More
Quantifying the Altruism Value for a Rare Pediatric Disease: Duchenne Muscular Dystrophy
January 14th 2025Altruism values for treatments of rare, severe pediatric diseases have not been estimated. This study found the altruism value for a hypothetical new Duchenne muscular dystrophy treatment to be $80 per year.
Read More